SI2861579T1 - Benzamidni derivati za inhibiranje aktivnosti ABL1, ABL2 in BCR-ABL1 - Google Patents

Benzamidni derivati za inhibiranje aktivnosti ABL1, ABL2 in BCR-ABL1 Download PDF

Info

Publication number
SI2861579T1
SI2861579T1 SI201330997T SI201330997T SI2861579T1 SI 2861579 T1 SI2861579 T1 SI 2861579T1 SI 201330997 T SI201330997 T SI 201330997T SI 201330997 T SI201330997 T SI 201330997T SI 2861579 T1 SI2861579 T1 SI 2861579T1
Authority
SI
Slovenia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
methyl
amino
Prior art date
Application number
SI201330997T
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Pascal Furet
Robert Martin Grotzfeld
Darryl Brynley Jones
Paul Manley
Andreas Marzinzik
Xavier Francois Andre Pelle
Bahaa Salem
Joseph Schoepfer
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48670630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2861579(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2861579T1 publication Critical patent/SI2861579T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (18)

  1. EP 2861579 BI Benzamidni derivati za inhibiranje aktivnosti ABL1, ABL2 in BCR-ABL1 Patentni zahtevki
    1. Spojina s formulo (I): v kateri:
    Ri je pirazolil; kjer je pirazolil nesubstituiran ali substituiran z 1-2 skupinama R^ R2 je pirolidinil; kjer je pirolidinil substituiran z eno skupino R7; R3 je izbran izmed vodika in halo; Rt je izbran izmed -SF5 in -Y2-CF2-Y3; R<5 je vsakokrat, kadar se pojavi, neodvisno izbran izmed vodika, hidroksi, metila, metoksi, ciano, trifluorometila, hidroksi-metila, halo, amino, fluoro-etila, etila in ciklopropila; R7 je izbran izmed hidroksi, metila, halo, metoksi, hidroksi-metila, amino, metil-amino, amino-metila, trifluorometila, 2-hidroksipropan-2-ila, metil-karbonil-amino, dimetil-amino, 2-amino-3-metilbutanoil)oksi, karboksi, metoksi-karbonila, fosfonooksi, ciano in amino-karbonila; Y je izbran izmed CH in N; Yi je izbran izmed CH in N; Y2 je izbran izmed CF2, O in S(O)0.2; in Y3 je izbran izmed vodika, kloro, fluoro, metila, difluorometila in trifluorometila; ali farmacevtsko sprejemljive soli le-te.
  2. 2. Spojina po zahtevku 1 s formulo (Ib): v kateri:
    R3 je izbran izmed vodika in halo; R4 je izbran izmed -SF5 in -Y2-CF2-Y3; Rg je, kadar je vezan na dušik pirazolilnega obroča, izbran izmed vodika, metila, fluoro-etila, etila in ciklopropila; in R$ je, kadar je vezan na atom ogljika pirazolilnega obroča, izbran izmed vodika, hidroksi, metila, metoksi, dano, trifluorometila, hidroksi-metila, halo, amino, fluoro-etila, etila in ciklopropila; R7 je izbran izmed hidroksi, metila, halo, metoksi, hidroksi-metila, amino, metil-amino, amino-metila, trifluorometila, 2-hidroksipropan-2-ila, metil-karbonil-amino, dimetil-amino, 2-amino-3-metilbutanoil)oksi, karboksi metoksi-karbonila, fosfonooksi, ciano in aminokarbonila; Yi je izbran izmed CH in N; Y2 je izbran izmed CF2,0 in S(0)o-2; Y3 je izbran izmed vodika, fluoro, kloro, metila, difluorometila in trifluorometila; ali farmacevtsko sprejemljive soli le-te.
  3. 3. Spojina po zahtevku 2 s formulo (Ic):
    v kateri: R3 je izbran izmed vodika in halo; R4 je izbran izmed -SF5 in -Y2-CF2-Y3; R$ je, kadar je vezan na dušik pirazolilnega obroča, izbran izmed vodika, metila, fluoro-etila, etila in ciklopropila; in je, kadar je vezan na atom ogljika pirazolilnega obroča, izbran izmed vodika, hidroksi, metila, metoksi, ciano, trifluorometila, hidroksi-metila, halo, amino, fluoro-etila, etila in ciklopropila; R7 je izbran izmed hidroksi, metila, halo, metoksi, hidroksi-metila, amino, metil-amino, amino-metila, trifluorometila, 2-hidroksipropan-2-ila, metil-karbonil-amino, dimetil-amino, 2-amino-3-metilbutanoil)oksi, karboksi, metoksi-karbonila, fosfonooksi, ciano in amino-karbonila; Yi je izbran izmed CH in N; Y2 je izbran izmed CF2, O in S(O)0.2; Y3 je izbran izmed vodika, fluoro, kloro, metila, difluorometila in trifluorometila; ali farmacevtsko sprejemljive soli le-te.
  4. 4. Spojina po zahtevku 3 ali farmacevtsko sprejemljiva sol le-te, izbrana izmed:
  5. 5. Spojina po zahtevku 3 ali farmacevtsko sprejemljiva sol le-te, izbrana izmed:
  6. 6. Spojina po zahtevku 3 ali farmacevtsko sprejemljiva sol le-te, izbrana izmed:
  7. 7. Spojina po zahtevku 1 ali farmacevtsko sprejemljiva sol le-te, kije:
  8. 8. Spojina, izbrana izmed:
  9. 9. Spojina po zahtevku 1, ki je (R)-N-(4-(klorodifluorometoksi)fenil)-6-(3-hidroksipirolidin-l-il)-5-(lH-pirazol-5-il)nikotinamid ali farmacevtsko sprejemljiva sol le-tega.
  10. 10. Farmacevtski sestavek, ki obsega amorfno disperzijo (R)-N-(4-(klorodifluorometoksi)fenil)-6-(3-hidroksipirolidin-l-il)-5-(lH-pirazol-5-il)nikotinamida in 1-2 ekscipienta, izbrana izmed PVP VA64 in Pharmacoat 603.
  11. 11. Sestavek po zahtevku 10, kjer je delež Pharmacoat 603 v območju 30-45 %, delež PVP VA64 je v območju 30-45 % in delež (R)-N-(4-(klorodifluorometoksi)fenil)-6-(3-hidroksipirolidin-l-il)-5-(lH-pirazol-5-il)nikotinamida je v območju 20-30 %.
  12. 12. Sestavek po zahtevku 11, kjer je delež Pharmacoat 603 37,5 %, delež PVP VA64 je 37,5 % in delež (R)-N-(4-(klorodifluorometoksi)fenil)-6-(3-hidroksipirolidin-l-il)- 5-(lH-pirazol-5-il)nikotinamida je 25 %.
  13. 13. Spojina s formulo (I) ali farmacevtsko sprejemljiva sol le-te po katerem koli od zahtevkov 1-9 za uporabo pri zdravljenju raka.
  14. 14. Spojina s formulo (I) ali farmacevtsko sprejemljiva sol le-te za uporabo po zahtevku 13, kjer je rak levkemija, izbrana izmed kronične mieloične levkemije in akutne limfoblastne levkemije.
  15. 15. Spojina s formulo (I) ali farmacevtsko sprejemljiva sol le-te za uporabo po zahtevku 13 ali 14 skupaj z dodatno spojino, izbrano izmed imatiniba, nilotiniba, dasatiniba, bosutiniba, ponatiniba in bafetiniba.
  16. 16. Spojina s formulo (I) ali farmacevtsko sprejemljiva sol le-te za uporabo po zahtevku 15 pri zaporednem ali sočasnem dajanju z dodatno spojino, kjer je dodatna spojina nilotinib.
  17. 17. Spojina s formulo (I) ali farmacevtsko sprejemljiva sol le-te za uporabo po katerem koli od zahtevkov 13-16, kjer je spojina (R)-N-(4-(klorodifluorometoksi)fenil)-6-(3-hidroksipirolidin-l-il)-5-(lH-pirazol-5-il)nikotinamid ali farmacevtsko sprejemljiva sol le-tega.
  18. 18. Farmacevtski sestavek, ki obsega spojino ali farmacevtsko sprejemljivo sol le-te po katerem koli od zahtevkov 1-9 skupaj z enim ali več farmacevtsko sprejemljivimi nosilci.
SI201330997T 2012-05-15 2013-05-09 Benzamidni derivati za inhibiranje aktivnosti ABL1, ABL2 in BCR-ABL1 SI2861579T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261647174P 2012-05-15 2012-05-15
US201361790967P 2013-03-15 2013-03-15
PCT/IB2013/053768 WO2013171639A1 (en) 2012-05-15 2013-05-09 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
EP13730652.8A EP2861579B9 (en) 2012-05-15 2013-05-09 Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1

Publications (1)

Publication Number Publication Date
SI2861579T1 true SI2861579T1 (sl) 2018-05-31

Family

ID=48670630

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330997T SI2861579T1 (sl) 2012-05-15 2013-05-09 Benzamidni derivati za inhibiranje aktivnosti ABL1, ABL2 in BCR-ABL1

Country Status (50)

Country Link
US (2) US8829195B2 (sl)
EP (1) EP2861579B9 (sl)
JP (1) JP6078639B2 (sl)
KR (1) KR102091893B1 (sl)
CN (1) CN104302638B (sl)
AP (1) AP3613A (sl)
AR (1) AR091063A1 (sl)
AU (1) AU2013261127B2 (sl)
BR (1) BR112014026383B1 (sl)
CA (1) CA2868958C (sl)
CL (1) CL2014002757A1 (sl)
CO (1) CO7131380A2 (sl)
CR (1) CR20140519A (sl)
CU (1) CU24265B1 (sl)
CY (2) CY1120235T1 (sl)
DK (1) DK2861579T5 (sl)
DO (1) DOP2014000256A (sl)
EA (1) EA024391B1 (sl)
ES (1) ES2670601T3 (sl)
FR (1) FR22C1053I2 (sl)
GE (1) GEP201606532B (sl)
GT (1) GT201400253A (sl)
HK (1) HK1203495A1 (sl)
HR (1) HRP20180695T1 (sl)
HU (2) HUE039138T2 (sl)
IL (1) IL235566A (sl)
JO (1) JO3453B1 (sl)
LT (2) LT2861579T (sl)
MA (1) MA37519B1 (sl)
ME (1) ME03095B (sl)
MX (1) MX359014B (sl)
MY (1) MY169377A (sl)
NL (1) NL301201I2 (sl)
NO (1) NO2022043I1 (sl)
NZ (1) NZ701626A (sl)
PE (3) PE20150669A1 (sl)
PH (1) PH12014502531B1 (sl)
PL (1) PL2861579T3 (sl)
PT (1) PT2861579T (sl)
RS (1) RS57177B1 (sl)
SG (1) SG11201407152XA (sl)
SI (1) SI2861579T1 (sl)
SV (1) SV2014004850A (sl)
TN (1) TN2014000427A1 (sl)
TR (1) TR201807023T4 (sl)
TW (1) TWI560183B (sl)
UA (1) UA113208C2 (sl)
UY (1) UY34811A (sl)
WO (1) WO2013171639A1 (sl)
ZA (1) ZA201407065B (sl)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200127273A (ko) 2012-04-26 2020-11-10 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피라진 유도체
MX2014013373A (es) * 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
CA2868958C (en) * 2012-05-15 2020-09-01 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
JP6080947B2 (ja) 2012-05-15 2017-02-15 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
WO2013171642A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (me) 2013-01-15 2021-04-20 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
PE20160532A1 (es) 2013-08-23 2016-05-21 Incyte Corp Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim
US9682931B2 (en) * 2013-11-01 2017-06-20 Ube Industries, Ltd. Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CN104478911A (zh) * 2014-12-19 2015-04-01 成都安斯利生物医药有限公司 一种制备3-三氟甲基吡咯硼酸的方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
EP3789027A1 (en) * 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
TN2017000375A1 (en) 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3448852A4 (en) * 2016-04-29 2019-04-10 Astar Biotech LLC NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018060843A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Surfactant systems for crystallization of organic compounds
US20190240176A1 (en) * 2016-10-26 2019-08-08 The University Of Georgia Research Foundation, Inc. Methods of treatment for myeloid leukemia
JP7234128B2 (ja) * 2017-03-15 2023-03-07 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド シクロプロパンカルボン酸（５－｛５－［ｎ’－（２－クロロ－６－メチルベンゾイル）ヒドラジノカルボニル］－２－メチル－フェニルエチニル｝－ピリジン－２イル）アミドの新規非晶質分散体
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JPWO2018216705A1 (ja) * 2017-05-23 2020-03-26 国立大学法人京都大学 神経変性疾患の予防及び／又は治療剤
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
CN112312904A (zh) * 2018-04-16 2021-02-02 C4医药公司 螺环化合物
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
KR102618168B1 (ko) * 2018-07-06 2023-12-27 일양약품주식회사 프리온 질환의 예방 또는 치료를 위한 약제학적 조성물
KR102119150B1 (ko) 2018-10-23 2020-06-04 한국원자력의학원 N-1h-벤지미다졸-2-일-3-(1h-피롤-1-일) 벤자미드를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
US11236070B2 (en) 2019-05-16 2022-02-01 Novartis Ag Chemical process
US11407735B2 (en) 2019-05-16 2022-08-09 Novartis Ag Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide
GB201913110D0 (en) * 2019-09-11 2019-10-23 Benevolentai Bio Ltd New compounds and methods
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114728943A (zh) * 2020-01-19 2022-07-08 正大天晴药业集团股份有限公司 作为bcr-abl抑制剂的化合物
EP4353230A3 (en) 2020-01-28 2024-06-19 Teva Pharmaceuticals International GmbH Solid state forms of asciminib and process for preparation thereof
WO2021156360A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
CN111321200A (zh) * 2020-02-28 2020-06-23 广州安镝声生物医药科技有限公司 一种细胞外abl1激酶活性检测试剂盒及其应用
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2022206937A1 (zh) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
EP4337205A1 (en) 2021-05-11 2024-03-20 Novartis AG Dosing regimens
KR20240014478A (ko) 2021-05-28 2024-02-01 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcr-abl 억제제로 사용되는 화합물
CN114149409B (zh) * 2021-11-16 2024-03-22 中国药科大学 一种具有蛋白激酶抑制活性的（杂）芳基酰胺类化合物
CN116135851A (zh) * 2021-11-17 2023-05-19 武汉众诚康健生物医药科技有限公司 一种芳香胺化合物及其应用
WO2023114759A2 (en) * 2021-12-13 2023-06-22 The Regents Of The University Of California Abl inhibitors and uses thereof
CN115109048B (zh) * 2022-08-10 2023-12-08 中国药科大学 一种(杂)芳基酰胺类化合物
WO2024100212A1 (en) 2022-11-10 2024-05-16 Synthon B.V. Crystalline form of asciminib hydrochloride

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2845997A1 (de) 1978-10-23 1980-04-30 Bayer Ag Pflanzenwachstumsregulierende mittel, verfahren zu ihrer herstellung und ihre verwendung zur regulierung des pflanzenwachstums
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
EP0333791A1 (de) 1987-09-23 1989-09-27 Ciba-Geigy Ag Heterocyclische verbindungen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
CA2397493A1 (en) 2000-01-27 2001-08-02 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2003039529A1 (en) 2001-11-07 2003-05-15 4Sc A.G. Selective antibacterial agents
AU2002367087A1 (en) 2001-12-21 2003-07-15 7Tm Pharma A/S Method for the treatment of mc receptor related disorders with a chelate and/or a chelator
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US8030336B2 (en) 2002-12-13 2011-10-04 Ym Biosciences Australia Pty Ltd Nicotinamide-based kinase inhibitors
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20080167347A1 (en) 2005-01-20 2008-07-10 Shiongi & Co., Ltd. Ctgf Expression Inhibitor
EP1881961A1 (en) 2005-05-11 2008-01-30 Novo Nordisk A/S New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
WO2007002441A1 (en) 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
DK1746097T3 (da) 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem
KR20080109068A (ko) * 2006-04-05 2008-12-16 노파르티스 아게 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물
WO2008021725A2 (en) 2006-08-11 2008-02-21 Smithkline Beecham Corporation Chemical compounds
CA2667010A1 (en) 2006-10-20 2008-05-02 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
EP2097380A1 (en) * 2006-11-15 2009-09-09 High Point Pharmaceuticals, LLC New haloalkylsulfone substituted compounds useful for treating obesity and diabetes
JP5286281B2 (ja) * 2007-01-05 2013-09-11 ブリストル−マイヤーズ スクイブ カンパニー アミノピラゾールキナーゼ阻害剤
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2008124393A1 (en) 2007-04-04 2008-10-16 Irm Llc Benzothiazole derivatives and their use as protein kinase inhibitors
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
BRPI0815038A2 (pt) 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
WO2009039127A1 (en) 2007-09-17 2009-03-26 Abbott Laboratories Uracil or thymine derivative for treating hepatitis c
EA201001847A1 (ru) 2008-06-11 2011-08-30 Айрм Ллк Соединения и композиции, применяемые для лечения малярии
BRPI0920608A2 (pt) 2008-09-29 2019-09-24 Boehringer Ingelheim Int compostos quimicos
CN102548987B (zh) 2009-07-14 2014-04-16 江苏迈度药物研发有限公司 作为激酶抑制剂的氟取代化合物及其使用方法
JP2011057661A (ja) 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
KR101663637B1 (ko) 2009-11-13 2016-10-07 제노스코 키나아제 억제제
JO3634B1 (ar) * 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
SG182361A1 (en) 2010-01-29 2012-08-30 Hanmi Science Co Ltd THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
US9278910B2 (en) 2011-05-31 2016-03-08 Receptos, Inc. GLP-1 receptor stabilizers and modulators
JP6080947B2 (ja) 2012-05-15 2017-02-15 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するための化合物および組成物
CA2868958C (en) 2012-05-15 2020-09-01 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX2014013373A (es) * 2012-05-15 2015-08-14 Novartis Ag Derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1.
WO2013171642A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1

Also Published As

Publication number Publication date
ES2670601T9 (es) 2022-11-30
HUS2200046I1 (hu) 2022-11-28
TWI560183B (en) 2016-12-01
UA113208C2 (xx) 2016-12-26
AR091063A1 (es) 2014-12-30
ZA201407065B (en) 2016-08-31
FR22C1053I1 (fr) 2022-12-16
HUE039138T2 (hu) 2018-12-28
CA2868958A1 (en) 2013-11-21
CU20140131A7 (es) 2015-04-29
KR20150020170A (ko) 2015-02-25
PE20210667A1 (es) 2021-04-05
IL235566A0 (en) 2015-02-01
US8829195B2 (en) 2014-09-09
ME03095B (me) 2019-01-20
ES2670601T3 (es) 2018-05-31
WO2013171639A1 (en) 2013-11-21
RS57177B1 (sr) 2018-07-31
AP2014007992A0 (en) 2014-10-31
BR112014026383A2 (pt) 2017-06-27
EP2861579A1 (en) 2015-04-22
CY1120235T1 (el) 2019-07-10
PH12014502531A1 (en) 2015-01-12
IL235566A (en) 2016-09-29
SG11201407152XA (en) 2014-11-27
HRP20180695T1 (hr) 2018-06-01
US20130310395A1 (en) 2013-11-21
NL301201I2 (nl) 2022-12-07
AP3613A (en) 2016-02-29
BR112014026383B1 (pt) 2020-11-17
CR20140519A (es) 2015-03-26
MX2014013374A (es) 2015-01-16
FR22C1053I2 (fr) 2023-11-10
CY2022033I1 (el) 2023-01-05
PT2861579T (pt) 2018-04-27
PH12014502531B1 (en) 2015-01-12
TW201400471A (zh) 2014-01-01
NO2022043I1 (en) 2022-10-25
LTPA2022523I1 (sl) 2022-12-12
UY34811A (es) 2013-12-31
MX359014B (es) 2018-09-12
CL2014002757A1 (es) 2015-01-23
PE20161416A1 (es) 2017-01-08
CA2868958C (en) 2020-09-01
PL2861579T3 (pl) 2018-07-31
EP2861579B9 (en) 2018-08-29
NZ701626A (en) 2016-02-26
MA37519B1 (fr) 2017-03-31
AU2013261127A1 (en) 2014-11-20
CN104302638B (zh) 2016-08-24
GT201400253A (es) 2017-09-28
US20140343086A1 (en) 2014-11-20
DK2861579T3 (en) 2018-05-28
JP6078639B2 (ja) 2017-02-08
DOP2014000256A (es) 2015-02-27
AU2013261127B2 (en) 2015-03-12
TN2014000427A1 (en) 2016-03-30
PE20150669A1 (es) 2015-05-17
TR201807023T4 (tr) 2018-06-21
GEP201606532B (en) 2016-08-25
EP2861579B1 (en) 2018-02-21
MY169377A (en) 2019-03-26
LT2861579T (lt) 2018-05-10
CN104302638A (zh) 2015-01-21
CY2022033I2 (el) 2023-01-05
SV2014004850A (es) 2018-04-04
EA024391B1 (ru) 2016-09-30
DK2861579T5 (da) 2022-10-24
CU24265B1 (es) 2017-07-04
MA37519A1 (fr) 2016-06-30
HK1203495A1 (en) 2015-10-30
CO7131380A2 (es) 2014-12-01
KR102091893B1 (ko) 2020-03-23
JP2015521185A (ja) 2015-07-27
JO3453B1 (ar) 2020-07-05
EA201491824A1 (ru) 2015-02-27

Similar Documents

Publication Publication Date Title
SI2861579T1 (sl) Benzamidni derivati za inhibiranje aktivnosti ABL1, ABL2 in BCR-ABL1
AU2018256624A1 (en) JAK2 and ALK2 inhibitors and methods for their use
HRP20192224T1 (hr) Inhibitori proteinske kinaze c i metode za njihovu primjenu
HRP20180341T1 (hr) Derivati 6-(5-hidroksi-1h-pirazol-1-il)nikotinamida i njihova uporaba kao inhibitora phd
HRP20200274T1 (hr) Terapeutski aktivni spojevi i postupci njihove uporabe
SI3022192T1 (sl) Derivati piperidinil indola in njihova uporaba kot inhibitorji komplementnega faktorja B
HRP20180483T1 (hr) Spoj kinolona
JP2016506962A5 (sl)
HRP20161613T1 (hr) Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli
NZ705881A (en) Heteroaryl inhibitors of pde4
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
MY169986A (en) Benzimidazole-proline derivatives
GEP201706774B (en) Heterocyclyl compounds
AR074238A1 (es) Compuesto de n-{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4,1.0]hept-4-il]metil}-2-heteroarilamina, su uso para la preparacion de un medicamento util para el tratamiento de una enfermedad que requiere un antagonista del receptor de orexina humano y composicion farmaceutica que lo comprende
SI3074386T1 (sl) Novi aminopirimidinski derivati
JP2016528298A5 (sl)
MX345238B (es) (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
IN2014CN04127A (sl)
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
MX2022000826A (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
JP2014525420A5 (sl)
SI2738156T1 (sl) Spojine tetraciklina substituirane z 9-aminometilom
HRP20161797T1 (hr) Spojevi 1,3-oksazolidina ili 1,3-oksazinana kao antagonisti receptora oreksina
HRP20161237T1 (hr) Antimalarijski agensi